{"id":"sizofiran","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"sizofilan","offLabel":[],"synonyms":["sizofilan","sizofiran","schizophylan","schizophyllan","schizophyllane","shizophyllan","sonifilan"],"timeline":[],"approvals":[],"brandName":"Sizofilan","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine Sizofilan as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. This process is highly specific and allows Sizofilan to target the underlying cause of a particular disease or condition.","oneSentence":"Sizofilan is a small molecule that works by interacting with a specific target in the body to produce a therapeutic effect.","technicalDetail":"Sizofilan's mechanism of action is characterized by its high affinity for a specific receptor or enzyme, leading to a cascade of downstream effects that ultimately result in the desired therapeutic response."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4048","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SIZOFIRAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SIZOFIRAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:38:06.215758","biosimilars":[],"competitors":[],"genericName":"sizofiran","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01926821","phase":"PHASE1","title":"Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2013-05","conditions":["Cervical Cancer"],"enrollment":200,"completionDate":"2025-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7F763NNC9X","CHEBI":"CHEBI:50653","INN_ID":"6107","UMLSCUI":"C0036359","ChEMBL_ID":"CHEMBL2107997","KEGG_DRUG":"D01535","DRUGBANK_ID":"DB13128","PUBCHEM_CID":"24777","MESH_DESCRIPTOR_UI":"D012566"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Sizofilan, also known as Sonifilan, is being studied in clinical trials for its potential impact on the quality of life in patients with cervical cancer. The exact mechanism of Sizofilan is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}